

**Biota Holdings Limited**

ACN 006 479 081

10/585 Blackburn Road

Notting Hill VIC 3168

Australia

**T** +61 3 9915 3700**F** +61 3 9915 3702**E** [info@biota.com.au](mailto:info@biota.com.au)**W** [www.biota.com.au](http://www.biota.com.au)*For Immediate Release*

Melbourne, Australia — 31 July 2012

**Inavir<sup>®</sup> June Quarter (Q4) Royalty**

Biota Holdings Limited (ASX:BTA) today announced that Daiichi Sankyo Co., Ltd. have provided written confirmation that Inavir<sup>®</sup> gross sales were JP¥431 million and indicative royalties were A\$0.2 million for the three months ended 30 June 2012.

Royalties for the year to 30 June 2012 for Inavir<sup>®</sup> were A\$4.3 million.

**About Biota**

Biota is a leading anti-infective drug development company based in Melbourne Australia, with key expertise in respiratory diseases, particularly influenza. Biota developed the first-in-class neuraminidase inhibitor, zanamivir, subsequently marketed by GlaxoSmithKline as Relenza. Biota research breakthroughs include a series of candidate drugs aimed at treatment of respiratory syncytial virus (RSV) disease and Hepatitis C (HCV) virus infections. Biota has a well advanced program for human rhinovirus (HRV) infection with a completed Phase IIb study in asthmatic subjects.

In addition, Biota and Daiichi Sankyo co-own a range of second generation influenza antivirals, of which the lead product Inavir<sup>®</sup>, is marketed in Japan. Biota holds a contract from the US Office of Biomedical Advanced Research and Development Authority (BARDA) for the advanced development of laninamivir in the USA.

Relenza<sup>™</sup> is a registered trademark of the GlaxoSmithKline group of companies.

Inavir<sup>®</sup> is registered to Daiichi Sankyo.

**Investor / Analyst Enquiries**  
**Biota Holdings Limited**

Peter Cook

T: +61 3 9915 3720

Damian Lismore

T: +61 3 9915 3721

**Media Enquiries**

Nerida Mossop, Hinton &amp; Associates

T: +61 3 9600 1979 / M: +61 437 361 433

Felicity Williams, Hinton &amp; Associates

T: +61 3 9600 1979 / M: +61 416 770 012

**US Enquiries**

Hershel Berry, Blueprint Life Science Group

M: +1 415 505 3749